Ion Beam Applications

IBA states that the composition and responsibilities of its administrative, management and supervisory bodies are detailed in the Corporate governance statement section of the integrated report, with the philosophy, structure and general principles set out in the Corporate Governance Charter available on the company website. The Charter highlights IBA's history of innovation, patient care and commitment, and the company's dedication to operating responsibly, ethically and sustainably, with a strong presence in Belgium and global awareness. It emphasizes management responsibility to stakeholders, anchored in the Articles of Association (Articles 3 and 10). On board diversity, the Board and Nomination Committee acknowledge the benefits of diversity across employees, the Executive Management Team and the Board. As of December 31, 2024, the Board is composed of 44% women and 56% men, and 67% of members are independent. The list of members and the decision process of the board and its committees is described in the Members and decision process of the board of directors section.

IBA reports that a Sustainability Committee was set up in 2018 to inform the management and supervisory bodies about sustainability matters. Since October 2020, the Sustainability Committee has been treated as a full board meeting with sustainability as a specific topic, given its importance to IBA's strategy, and it was renamed the Sustainability Board. As of December 31, 2024, the Sustainability Board consists of all members of the Board of Directors. Bridging for Sustainability SRL, represented by its permanent representative Ms. Sybille van den Hove, chairs the meetings, which also involve the sustainability team and some members of the management team depending on the topics addressed. In October 2024, the Sustainability Board presented the action plan put in place across lines including climate change, resource and waste, diversity and governance, along with the status of each action. The implementation of CSRD was a dedicated point of the board, reviewing in particular the double materiality outcome, followed by specific CSRD training for board members in January 2025.

IBA reports that for year 2024, performance is measured against three elements: Profit Before Tax, Order Intake and Sustainability, weighted at 33%, 33% and 34% respectively. These targets are geared towards achieving and exceeding the company's fiscal year objectives and specific milestones on IBA's ESG goals. From year 2025, the plan includes the possibility of a differentiated fourth measure aligned with the strategic objectives of each business unit, in which case the weight of each measure would be set at 25%. Sustainability performance is measured against IBA's verified B Corp score, obtained via a third party independent proforma assessment. The target is set globally across the five B Corp impact areas of governance, employees, community, environment and customers, meaning there is no specific target set on any single sustainability dimension, in order to ensure a holistic improvement approach.

IBA provides a due diligence statement noting that CSRD disclosure requirements are set to expand and that the EU Directive on corporate sustainability due diligence (Directive 2024/1760, CSDDD), which came into force in 2024, will shape its future sustainability reporting by obliging IBA to manage and mitigate negative impacts on human rights and the environment throughout its value chain. The CSDDD is expected to apply to IBA from the 2028 financial year. IBA states it has proactively upgraded its supplier procurement program, treating suppliers as equal partners, and has established ethical principles set out in the IBA Code of Conduct for Suppliers, which is included in all contract templates and signed contracts and aligns with the United Nations Sustainable Development Goals. Since 2023, IBA uses EcoVadis to assess the social and environmental performance of its supply chain and to screen its main Tier 1 suppliers for compliance. A core elements of due diligence table maps each element to the relevant report sections and page references.

IBA reports that the Board of Directors, supported by the Management Team, the Risk Management Committee and the Audit Committee, oversees and manages enterprise risk. These committees have identified several functional experts to cover the various categories of enterprise risk. The Management Team and the Risk Management Committee work continuously to enhance the enterprise risk management framework and are responsible for implementing appropriate risk responses. IBA notes that the general approach and framework for risk management are further detailed in the Principal risks and uncertainties section of the management report. The risk management approach specific to sustainability is described in the Description of the process to identify and assess material impacts, risks, and opportunities (IRO-1) section of the Sustainability Statements.

IBA describes a business model built on being a force for good by creating shared and long-term value for all stakeholders. The company has been a Certified B Corporation since 2021 and uses the B Corp framework as a voluntary tool to assess, benchmark and improve its sustainability journey across five impact areas: governance, workers, community, environment and customers. Its sustainability strategy identified four strategic streams inspired by the B Corp certification process. IBA operates through four core activities: Industrial Solutions, RadioPharma Solutions, Proton Therapy and Dosimetry, offering solutions for diagnosing and treating cancer and other serious illnesses and for industrial applications such as sterilization of medical devices. Revenues per sector are disclosed in the management report. The value chain spans upstream suppliers (raw materials such as steel, composites and alloys, machining and assembly), own operations (innovation, development, assembly, testing), and downstream use of sold products, with accelerator-based systems lasting up to 30 years and dosimetry products up to 10 years, followed by decommissioning, upgrade or recycling under customer responsibility.

IBA frames its engagement with stakeholders through what it calls its Stakeholder Approach, which it describes as embodying a long-lasting societal commitment and a business model that acts as a force for good, creating shared and long-term value for all stakeholders. The company states that acting as a force for good is the most effective strategy to attract and retain talent, anticipate future risks, and enhance current product offerings while exploring new and emerging markets, in line with B Corp certification requirements across Environmental, Social and Governance areas. IBA's Articles of Association (articles 3 and 10) reflect its commitment to consider the impact of its activities on all stakeholders. IBA states it continuously engages with stakeholders through its activities, and these interactions provide insights into their positions, concerns and expectations. It notes that stakeholder views are further disclosed within each topical chapter of the Sustainability Statements.

IBA reports that its materiality exercise identified six material sustainability matters. Topics exceeding both the impact and financial materiality thresholds are Climate Change and Product Safety. The topic exceeding both thresholds also includes Circularity (Resources and Waste). Topics exceeding only the impact materiality threshold are Health, Safety and Well-being of own workforce and Product affordability and Accessibility. The topic exceeding only the financial materiality threshold is Business Ethics, Corruption and Fraud. A detailed table describes each material impact, risk and opportunity, its placement across upstream, own operations and downstream, whether it is negative or positive, actual or potential, its likelihood, time horizon and geographic scope, mapped to ESRS E1, E5, S1, S4 and G1. The six topics are reported across ESRS 2, E1, E5, S1, S4 and G1, with the EU Taxonomy disclosed in the climate change section. IBA states the double materiality assessment will be updated every other year or upon significant changes, and lists non-material topics screened out under ESRS E2, E3, E4, S2 and S3.

IBA describes a double materiality process covering impact materiality (inside-out) and financial materiality (outside-in). It has conducted systematic materiality assessments since 2017, initially guided by GRI criteria, and conducted the double materiality exercise in 2024 in accordance with ESRS 1 across its global value chain. Key activities included identifying the complete value chain, stakeholder engagement, listing IROs and their placement in the value chain, prioritizing IROs and setting thresholds, building a double materiality matrix, and gap analysis to identify data points to report. The IRO list was compiled from value chain analysis and a review of sector-specific IROs from GRI, SASB and MSCI ESG Ratings, plus ESRS 1 topics. Stakeholders were identified using criteria such as highly affected, highly dependent, high expertise and geography, and consulted through interviews, roundtables and online surveys. Impact materiality considered scale, scope, likelihood and irremediability, with a threshold of 65; financial materiality drew on the ERM system and ESRS screening, with a threshold of 70. The IBA risk scoring matrix was used to score risks.

IBA addresses the disclosure requirements covered by its statement. It reports that its six material topics are reported across the following ESRS standards: ESRS 2 General disclosures, ESRS E1 Climate change, ESRS E5 Resource use and circular economy, ESRS S1 Own workforce, ESRS S4 Consumers and end-users, and ESRS G1 Business conduct, with the EU Taxonomy disclosed in the climate change section. The statement notes that, under incorporation by reference, information published in other parts of the annual report is cross referenced through an ESRS cross-reference table where appropriate. IBA also uses the phase-in option to omit all phase-in information required by ESRS 2 SBM-3 (DR48e), ESRS E1-9, ESRS E5-6, ESRS S1-7 (DR55), ESRS S1-14 (DR88d,e) and ESRS S1-15 (DR93,94) in accordance with Appendix C of ESRS 1. Topics screened as not material fall under ESRS E2, E3, E4, S2 and S3.

IBA reports a transition plan for climate change mitigation, framed by its 'Low carbon value chain' stream, one of four sustainability strategic streams. Following the GHG Protocol, IBA splits emissions into scope 1 (direct), scope 2 (purchased electricity) and scope 3 (other value chain emissions). Scope 1 and 2 are driven mainly by heating, purchased electricity for facilities, and fuel and electricity for company cars; measures include a green car policy, increasing renewable electricity autoproduction and sourcing renewable electricity. The majority of emissions are scope 3, primarily from the use of products sold, influenced by product energy efficiency and destination-country electricity mixes. Scope 3 actions include ecodesign in R&D, improving product energy efficiency, engaging suppliers, favoring lower-impact shipping, optimizing business travel, and promoting renewable energy to customers. Locked-in emissions arise from fossil heating and grid mix (scope 1+2) and from the product use phase (scope 3). The plan was validated by IBA's Sustainability Board.

IBA reports policies related to climate change mitigation. Environmental policies on climate change mitigation derive from global IBA policies signed by the CEO, and are detailed under the Code of Business Conduct (G1-1) and ESRS E MDR-P. Their scope covers the full IBA value chain (upstream, own operations, downstream) and all geographies where IBA operates. The policies focus on climate change mitigation and improving energy efficiency, with renewable energy deployment and related topics indirectly captured under the commitment to 'Assess and reduce the greenhouse gas emissions'. The report explicitly states that, to date, climate change adaptation is not considered in the policies. The latest Code of Business Conduct (2024 version) is published on IBA's website. IBA also has a Code of Conduct for Suppliers covering minimum environmental standards expected of suppliers, following United Nations guidelines and aligning with relevant Sustainable Development Goals.

IBA reports actions and resources for its climate policies, all implemented in 2024 with allocated financial and human resources. Innovation and development introduces lower-carbon products: the Proteus ONE proton therapy system (superconductivity, saving electricity and concrete versus multi-room configurations), the Cyclone KIUBE, the compact IntegraLab ONE radiopharmacy, and a new-generation Rhodotron. Remote, predictive and preventive maintenance reduces service travel. Employee mobility includes a 2023 car policy enforcing 100% electric vehicles for new Belgian fleet orders, a 500 kW photovoltaic car port, 120+ charging points, and 250+ leased bicycles (20%+ uptake). Renewable energy covers 90%+ of group electricity, including a 750 kWc photovoltaic installation in Belgium. Low-impact shipment shifted US return logistics to shared container shipping. Since 2023 IBA uses EcoVadis to assess Tier 1 suppliers, and in 2025 intends to set improvement targets. Actions map to scopes, time horizons and, in several cases, to E1-4 targets.

IBA reports climate targets. For scope 1 and 2, it targets a reduction of at least 50% below 2018 levels by 2030, inspired by EU climate targets; IBA notes this target is not compatible with limiting warming to 1.5 degrees Celsius per SBTi guidance. A separate energy intensity target aims to cut financial energy intensity (MWh of scope 1 and 2 per million euro revenue) by 50% below 2020 levels by 2030, from a 45.8 MWh/MEUR baseline to 22.9 MWh/MEUR; at end 2024 it stood at 29.3 MWh/MEUR. Scope 3 targets are not yet formally set; in 2024 IBA ran a study with CO2Logic (a South Pole company) using 2022 as base year to prepare a potential SBTi submission, with internal validation and an SBTi commitment decision due in 2025. An upstream target aims to cover more than 50% of Tier 1 supplier spending through EcoVadis assessment by end 2025 (from 0% in 2023); 49% of Tier 1 suppliers had an EcoVadis scorecard at end 2024. External stakeholders did not participate in setting targets.

IBA reports energy consumption and mix covering major plants, offices and activities in Belgium, Germany, China, Canada and the Portugal acquisition, fully covered by primary data and not externally verified. Total energy consumption was 14,611 MWh in 2024, down from 15,703 MWh in 2023 and 15,849 MWh in 2022. In 2024, total fossil energy consumption was 8,109 MWh (56% share), comprising crude oil and petroleum products (5,882 MWh), natural gas (2,017 MWh) and purchased electricity, heat, steam and cooling from fossil sources (210 MWh). Nuclear consumption was 296 MWh (2%). Total renewable energy consumption was 6,205 MWh (42% share), including 5,529 MWh of purchased renewable electricity, heat, steam and cooling and 676 MWh of self-generated non-fuel renewable energy. Renewable energy production was 676 MWh. Energy consumption in high climate impact sectors per net revenue was 29 MWh per million euro in 2024, down from 37 (2023) and 44 (2022).

IBA reports gross scope 1, 2, 3 and total GHG emissions following the GHG Protocol, using ADEME, IEA and DEFRA/BEIS emission factors and IPCC 100-year GWP, supported by CO2Logic; figures are not externally verified. Gross scope 1 was 1,726 tCO2eq in 2024 (2,187 in 2023). Scope 2 location-based was 1,017 tCO2eq and market-based 156 tCO2eq. Combined scope 1+2 location-based was 2,743 tCO2eq in 2024, down 48% from the 2018 base year of 5,313 tCO2eq, against a 2030 target of 2,657 tCO2eq (-50%); market-based scope 1+2 was 1,882 tCO2eq. Total gross scope 3 was 543,477 tCO2eq in 2024, dominated by use of sold products (442,740 tCO2eq), with purchased goods and services (80,086), business travel (7,686), upstream transportation (9,376) and capital goods (1,692). Total GHG emissions were 546,220 tCO2eq (location-based) and 545,359 tCO2eq (market-based). Only 1.6% of scope 3 was calculated using primary data. IBA reports a CDP Climate score of B in 2024. No biogenic emissions are declared.

IBA reports on GHG removals and carbon credits. It states there are 'no removals or storage related to IBA's own operations, nor within its upstream and downstream value chain, and there is no purchase of carbon credits'. Outside its value chain, for the fifth consecutive year, IBA supports European farmers transitioning to regenerative agriculture through its partnership with Soil Capital, helping integrate nitrogen-fixing vegetables into crop rotations. Through this program IBA has contributed to the regeneration of 4,700 hectares of farming soils, equivalent to 4,700 tons of CO2 reduced or removed. In 2024, IBA purchased 2,000 carbon farming certificates for the 2023 period, valued at the internal carbon price of 2023. These removals and certificates sit outside IBA's own value chain and are not used as offsets against reported scope 1, 2 or 3 emissions.

IBA reports an internal carbon price. Since 2021 IBA has set an internal shadow carbon price as a theoretical means to inform decisions about carbon reduction actions. It considers several references to align with market trends and sustainability goals: one primary reference is the price of allowances under an Emissions Trading Scheme (ETS), and a second is the cost of carbon certificates such as the carbon farming certificates referred to in E1-7, which support investments in projects that reduce or remove greenhouse gas emissions. In 2024, the internal carbon price is set at 96 euro per tonne of CO2e. The carbon farming certificates referenced in E1-7 were purchased at the internal carbon price; the certificates bought in 2024 for the 2023 period represent 2,000 tons of CO2e.

IBA's environmental policies on circularity (resource and waste) derive from global IBA policies signed by the CEO and detailed under the Code of Business Conduct (G1-1) and ESRS E MDR-P. Their scope covers IBA's whole value chain (upstream, own operations, downstream) and all geographies where IBA operates. The policies set out IBA's commitment to reducing waste production from its products, activities and value chain. To date they do not cover transitioning away from the use of virgin resources, sustainable sourcing, or the use of renewable resources. The latest Code of Business Conduct (2024 version) is published on IBA's website. IBA has also implemented a Code of Conduct for Suppliers setting minimum environmental standards expected of all suppliers within their sphere of influence, following and supporting the UN Sustainable Development Goals by aligning its principles with relevant SDGs.

IBA applies circularity principles (avoid, reduce, reuse, recycle) through ecodesign across its four business lines (Proton Therapy, RadioPharma Solutions, Dosimetry, Industrial Solutions), all designed for maintenance and servicing over their lifespan. Actions include designing for repairability and upgradability (since 1986), extending product lifetime (a 2024 contract to restore a 25-year-old proton therapy center, plus Rhodotron refurbishment and RadioPharma accelerator relocation), and Low Activation Concrete (2015) to cut dismantling waste. IBA eliminates toxic sterilization waste via Rhodotron E-beam/X-ray solutions replacing ethylene oxide and cobalt-60, and is studying a PFAS destruction method using particle accelerators. It reduces waste at source with recycled-material packaging machines (a low-impact packaging program launches in 2025), runs low-impact reverse logistics (sea over air freight since 2023), offers decommissioning guidance and the CYCLADE decommissioning partnership (2023), and since 2023 uses EcoVadis to assess Tier 1 suppliers (over 100kEUR spend or critical parts).

IBA set voluntary targets acting at the recycling layer of the waste hierarchy to increase recyclability of waste produced and circular material use by others. The waste intensity target is to reduce unsorted (mixed) waste financial intensity by a factor of 3 (15% per year) below 2018 levels by 2025. The hazardous waste intensity target is to reduce hazardous waste financial intensity by 10% below 2020 levels by 2025. An upstream supply chain target aims to cover, by end of 2025, more than 50% of Tier 1 supplier spending through EcoVadis ESG assessment, compared to 0% in 2023; at end of 2024, 49% of Tier 1 suppliers had an EcoVadis scorecard. Targets are not associated with circular design, waste management treatment, or sustainable sourcing, as IBA has no plans to set such targets. External stakeholders did not participate in setting the targets, which are assessed at each Sustainability Board meeting.

IBA describes two resource inflows: custom components manufactured by external suppliers to IBA-owned designs, and standard electromechanical commodity components purchased directly from the market, combined during assembly, testing and delivery. The primary components of IBA's accelerators by mass are steel, copper and aluminum, with smaller quantities of lead, plastics (petrochemical-derived), and various electromechanical products that may include rare earth elements, rare elements, gold and cobalt. Supplier and logistics packaging mainly consists of cardboard, wood and steel. In 2024, the total weight of materials used to manufacture IBA's products was estimated at 1863 tons, based on the total mass of the bill of materials for products sold in 2023. IBA does not require certifications for sustainable sourcing, giving 0% biologically sourced sustainable materials. As IBA received no information on secondary reused or recycled components from suppliers, it assumes 0% secondary or recycled components are used in its products.

IBA accelerator products last up to 30 years and dosimetry products have a 10-year lifespan; no industry averages are publicly available for comparison. All products are designed for maintenance and servicing, are repairable and some retrofittable at end-of-life, though no established repairability rating applies to IBA's products. In 2024, 86% of the mass of accelerators sold is recyclable according to IBA's Bills of Materials. IBA product packaging uses fully recyclable materials (100%): wood, polyolefins, cardboard and steel. Total waste generated (hazardous, non-hazardous and radioactive) was 225.4 tonnes in 2024, up from 197.0 t (2023) and 177.1 t (2022). Non-recycled waste was 72.6 t in 2024, a 32.2% share of non-recycled waste (down from 35.2% in 2023 and 42.2% in 2022). Figures cover major manufacturing facilities and offices in Belgium, Germany, China, Canada and Portugal, are calculated by IBA and have not undergone external verification.

IBA reports waste for facilities in Belgium, Germany, China, Canada and Portugal (2022 and 2023 restated to include the Portugal acquisition). Total waste generated was 225.4 t in 2024 (197.0 t in 2023; 177.1 t in 2022). Hazardous waste rose to 13.5 t in 2024 (6.7 t 2023; 2.6 t 2022), of which 0.6 t was directed to disposal (0.6 t incineration, 0.008 t landfilling) and 12.9 t diverted from disposal through recycling. Non-hazardous waste totalled 211.9 t in 2024 (190.3 t 2023; 174.5 t 2022): 72.0 t directed to disposal (66.1 t incineration, 5.9 t landfilling) and 139.9 t diverted via recycling. Radioactive waste was 0.0 t across all years. Paper, cardboard and wood (transport packaging) make up about 53% of total waste. By stream in 2024: paper and cardboard 88.1 t, mixed/unsorted 74.0 t, wood 32.7 t, metal 11.1 t, WEEE 10.9 t, plastics 4.6 t, chemicals 2.6 t, glass 1.3 t. Hazardous waste financial intensity rose to 0.027 t/mEUR in 2024 (up from base year), driven by building upgrades and WEEE collection of non-repairable electrical parts. Mixed waste intensity fell to 0.15 t/mEUR (-42% vs 2018 base), still behind the 2025 target of 0.08.

IBA reports its own-workforce policies. The Code of Business Conduct (2024 version) sets out the principles of its social and staff-related policy and is based, among others, on the International Labour Organization's Declaration on Fundamental Principles and Rights at Work. IBA commits to a positive, productive and safe work environment free from violence, threats, harassment, intimidation and coercion, and it protects social rights, including free membership or non-membership of a trade union. Health and safety policies cover all employees plus subcontractors and visitors, with focus on manufacturing at headquarters and installation on customer sites. Essential H&S requirements are managed under EU Medical Device Regulation (MDR) 2017/745, and ISO 45001 certification is targeted by the end of 2026. Further policies include machine safety systems, PPE protocols, a right to disconnect policy, active human rights protection (forbidding involuntary labour, human trafficking and underage labour), and a Data Handling Policy for GDPR compliance.

IBA describes its processes for engaging with its own workforce. Implementation, monitoring and updating of policies are discussed in the Committee for Protection and Prevention at Work in Belgium, with similar committees existing in other countries. Through the At Our Best philosophy, IBA maintains a constant dialogue with employees, providing visibility into organizational health at all levels. A regular engagement survey process is in place: frequent feedback is collected from all employees through Pulse surveys (Glint), giving a real-time measure of engagement at both team and organization level. Managers receive real-time insights on engagement levels and organizational health, along with guidance to take effective actions, combined with LinkedIn Learning training materials.

IBA reports the channels available for its own workforce to raise concerns and the process to remediate negative impacts. If employees, whether as a victim or a witness, are confronted with the mentioned risks or behaviours, they have multiple channels to report a concern: their manager, the Human Resources team, the legal team and/or the IBA Compliance Officer. These channels are further described in the Business conduct policies and corporate culture disclosure (G1-1). The process to remediate negative impacts is further described in the policies related to own workforce disclosure (S1-1). Separately, all employees are encouraged to report any safety and health issue via a formal intranet reporting tool (Jira).

IBA describes actions taken on material impacts. On health and safety, IBA ensures operations comply with applicable occupational health and safety regulations and, where appropriate, implements additional controls; all employees are empowered to stop any activity they judge hazardous under the No Harm principle. Regarding working time, IBA respects rules on working hours, travel time and time to recover in the locations where it operates, with organizational measures to minimize impact on employees and respect personal time. On well-being, IBA has implemented initiatives to address psychosocial risks, including stress management workshops, mindfulness training and access to employee assistance programs (EAPs) offering confidential counseling, alongside team-building activities, open communication channels and supportive management. IBA states it has not identified negative impacts on its own workforce arising from its transition plan.

IBA discloses its targets related to own workforce. For health and safety, the targets are timely resolution of corrective and preventive actions EHS tickets (80% on time) and a number of fatalities equal to zero (No Harm). For well-being, IBA states it has not identified any material targets relevant to disclose. Regarding the involvement of stakeholders, IBA reports that stakeholders have not participated in setting these targets.

IBA reports employee characteristics in headcount at period end. The Group had 2,118 employees in 2024 (up from 1,986 in 2023 and 1,820 in 2022). The gender split remains stable at 27% women / 73% men / 0% other; by headcount that is 572 female, 1,545 male, 1 other in 2024. By region, EMEA is 71%, AM 18% and Asia 11%. Part-time employees are 8% and temporary staff 8%. Countries representing at least 10% of the workforce are Belgium (1,117), USA (343) and Germany (222). By contract type, there were 1,954 permanent and 164 temporary employees, and no non-guaranteed-hours employees. Well-being metrics for 2024 show turnover of 139 headcount (7% turnover rate) and a Glint engagement score of 75%.

IBA reports health and safety metrics for 2024. There were 19 recordable work-related accidents for its own workforce, at a rate of 5 recordable cases per million worked hours. There were zero fatalities in the own workforce as a result of work-related injuries and ill health, and zero fatalities among other workers working on the undertaking's sites. Timely resolution of corrective and preventive actions EHS tickets was 22%. 100% of the IBA workforce is covered by the health and safety management system.

IBA reports policies for consumers and end-users across two topics. On product safety, the mission to Protect, Enhance, and Save Lives is delivered by assuring products match their intended use and pose no danger to patients and users, and by maintaining the highest product quality and complying with all applicable regulations set by government agencies to protect public health. The Code of Business Conduct, built on the values Dare, Care, Share and Be Fair, covers device quality and regulations. Product quality is ensured by adhering to good manufacturing and laboratory practices and quality system requirements, properly registering and labeling products, promptly responding to complaints with timely corrective action, and promoting products with evidence-based claims. IBA's Data Handling Policy explains GDPR compliance to protect personal data of clients and patients. On affordability and accessibility, IBA states it has no formal policy, but these topics are an essential part of its business development strategies, again anchored in the Code of Business Conduct.

IBA describes engagement processes chiefly under affordability and accessibility. Its user community is deeply involved in advancing and widening access to IBA solutions, and IBA seeks input through various channels, regularly gathering customers, prospects, partners and its own team to share insights and exchange ideas. The Open Innovation Program invites innovators to submit disruptive project ideas, with selected proposals developing a proof-of-concept using IBA's expertise and resources; it is open to individuals, companies, universities and research centers. IBA expands accessibility through partnerships, engaging in associations that advocate for radiotherapy, proton therapy, industrial irradiation and sustainable development, and holds corporate memberships in organizations that educate insurers, policymakers, employers and the public about the clinical benefits of proton therapy, including iiA Global. It also engages through education, with employees sharing expertise at universities and high schools, such as the funded proton therapy engineering course at EPL. Patient engagement runs through the Oncia Community, a non-profit foundation endorsed by IBA supporting comprehensive cancer care centers.

IBA describes its remediation processes and grievance channels under product safety. It has established processes to collect, review, assess and provide feedback on all customer complaints in a timely manner. This includes collecting complaints from different sources, reviewing and analyzing them, assessing the need for reporting complaints linked to medical devices, maintaining complaint file records, and providing feedback to customers. In addition, concerns, faults and grievances can be reported by anyone through a whistleblower platform on the Company's website. This platform ensures confidentiality, complies with European and international standards, and allows for anonymous complaints.

On product safety, IBA validates the clinical efficacy and safety of proton therapy through Post Market Clinical Follow-up, combining literature review of patient outcomes with statistical analysis of patient registry data (such as the PCG US registry and a new European registry by IEO), plus passive surveillance and product risk management data, and a process to launch clinical investigations. IBA Dosimetry runs a Quality Management System compliant with ISO13485:2016 and FDA 21 CFR Part 820. Accelerator safety systems use automatic shutoffs, interlocks and emergency stops, with regular safety audits and user training. Certifications include ISO9001, ISO13485, MDD and MDSAP, with the MDR certificate received in March 2025. On affordability and accessibility, IBA works to make cancer treatment widely available and affordable through theranostics and the PanTera joint venture with SCK CEN, makes diagnosis more accessible by reducing radiopharmacy size and via the Cyclone KEY cyclotron for local FDG and PET imaging, and expands treatment modalities by supporting the PROTECT Trial and developing the compact multi-ion C400 IONS system.

IBA reports metrics and targets across both topics. On product safety, all activities target a positive impact on people's health by providing healthcare professionals with effective and accurate solutions for diagnosis, treatment and sterilization, and IBA states there have been no material incidents of non-compliance with regulations and voluntary codes concerning the health and safety impacts of its products and services. On affordability and accessibility, by the end of 2024 over 140,000 patients had been treated using IBA proton therapy equipment and more than 700 accelerators had been sold worldwide across its four business units, illustrating IBA's reach. However, given the complex interplay of product development, community awareness, healthcare providers and regulatory bodies, IBA states that at this stage it has not identified any metrics or targets that would meaningfully and holistically illustrate progress on affordability and accessibility.

IBA describes a collaborative corporate culture built on its Stakeholder Approach and core values (Dare, Care, Share, Be Fair), aiming to conduct business honestly, ethically and with integrity. The main policy is the Code of Business Conduct, a living document last updated in 2024, signed by the CEO and published on IBA's website. It applies to all employees and consultants, who must certify they have received, read and understood it; certification is a condition of employment and non-compliance may lead to disciplinary sanctions. The Code sets out 12 key principles covering conflicts of interest, records and internal controls, fair competition, medical device quality, international trade, political involvement, information and IP, data privacy, environment, health and safety, anti-bribery and human rights. A formal reporting system and an anonymous whistleblower platform (active since December 2021) exist. The Chief Compliance Officer monitors compliance and reports to the Audit Committee. In 2024, 72 percent of employees signed the Code and 75 percent were trained (80 percent quiz pass required). A Dealing Code prevents insider trading.

IBA's anticorruption policy aims to prevent and prohibit bribery and any form of corruption, seeking compliance with applicable anti-corruption and bribery legislation including Belgian, European, United States and other international anti-corruption laws. IBA states it is not aware of any infringement of these laws and closely monitors its business practices within the Group. The Code of Business Conduct defines the strict framework for conducting business, including an unambiguous rejection of corruption and bribery risks: bribery of any government official in any country or of any private person, as well as corrupt practices, are strictly against policy, even if refusing to make such payment would cost a business opportunity. Employees and representatives must not accept or offer gifts or favors of any kind from or to a business partner, except courtesy gifts of modest value at an appropriate time and place, and never where they may affect the integrity or independence of the parties. Related monitoring and controls are detailed under G1-1.

Over 2024, IBA reports it did not receive any complaints relating to the Code of Business Conduct. IBA conducts due diligence and ensures the mandatory use of approved contract templates for new and renewing partners. It remediates upon discovery or strong suspicion with immediate termination and notification of relevant authorities. The reported metrics show, for 2022, 2023 and 2024, zero convictions for violation of anti-corruption and anti-bribery laws and zero euros in fines for such violations in each of those years. Under targets, IBA states its aim is to maintain its achievement of having no third-party providers, customers or partners involved in any corrupt practices, and is committed to continuing this standard.

IBA regularly interacts with government officials in conducting business globally and requires employees to seek proper guidance and obtain required approvals from hierarchy or the IBA Legal Team before engaging in government or political activities. Lobbying, defined as influencing public policy decisions, is strictly regulated under the Code of Business Conduct and requires management approval. In 2024, IBA did not directly engage in lobbying activities, political influence or contributions (0 keur). IBA indirectly engages in lobbying through membership in associations advocating for radiotherapy, proton therapy, industrial irradiation and sustainable development, including ASTRO, ESTRO, EANM, AAPM, NAPT, the Alliance for Proton Therapy, iiA Global, COCIR, The Shift, the Brabant-Wallon Alliance (ACBW) and the B Corp community. On transparency, IBA meets its obligations by incorporating sustainability information into publicly available company reports and states it is not registered in a transparency register.